Hexosamine analogs: from metabolic glycoengineering to drug discovery

Current Opinion in Chemical Biology

Volumn 13, Issue 5-6, 2009, Pages 565-572

  Wang, Zhiyun ^a   Du, Jian ^a   Che, Pao Lin ^a   Meledeo, M Adam ^a   Yarema, Kevin J ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BIOPOLYMER; CARBOHYDRATE; DISACCHARIDE; GLYCAN; HEPARIN; HEXOSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOSACCHARIDE; NUCLEIC ACID; PROTEIN;

BINDING AFFINITY; BIOSYNTHESIS; CHEMICAL STRUCTURE; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG DESIGN; GLYCOBIOLOGY; GLYCOSYLATION; HYDROLYSIS; METABOLIC ENGINEERING; METABOLIC GLYCOENGINEERING; REVIEW;

ANIMALS; BIOENGINEERING; BIOLOGICAL PRODUCTS; BIOPOLYMERS; DRUG DISCOVERY; HEXOSAMINES; HUMANS;

ANIMALIA; MAMMALIA;

EID: 70549098258     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.08.001     Document Type: Review

References (53)

1. Kobata A. The third chains of living organisms - a trail of glycobiology that started from the third floor of building 4 in NIH. Arch Biochem Biophys 426 (2004) 107-121
2. Campbell C.T., Sampathkumar S.-G., Weier C., and Yarema K.J. Metabolic oligosaccharide engineering: perspectives, applications, and future directions. Mol Biosyst 3 (2007) 187-194. This article provides an introduction to metabolic glycoengineering for the nonspecialist.
3. Werz D.B., Ranzinger R., Herget S., Adibekian A., von der Lieth C.-W., and Seeberger P.H. Exploring the structural diversity of mammalian carbohydrates ("glycospace") by statistical databank analysis. ACS Chem Biol 2 (2007) 685-691
4. Campbell C.T., and Yarema K.J. Large-scale approaches for glycobiology. Gen Biol 6 (2005) article 236
5. Wang A., Nairn N.W., Johnson R.S., Tirrell D.A., and Grabstein K. Processing of N-terminal unnatural amino acids in recombinant human interferon-b in Escherichia coli. ChemBioChem 9 (2008) 324-330. This article provides an example of metabolic substrate-based methodology used to introduce abiotic amino acids into proteins illustrating challenges faced compared to the more facile biosynthetic incorporation of non-natural monosaccharides into glycoconjugates.
6. Kwon I., and Tirrell D.A. Site-specific incorporation of tryptophan analogues into recombinant proteins in bacterial cells. J Am Chem Soc 129 (2007) 10431-10437
7. Yia W., Liu X., Li Y., Lie J., Xia C., Zhou G., Zhang W., Zhao W., Chen X., and Wang P.G. Remodeling bacterial polysaccharides by metabolic pathway engineering. Proc Natl Acad Sci U S A 106 (2009) 4207-4212. This article outlines recent progress in adapting metabolic glycoengineering to bacterial systems; this approach promises to provide a general, facile, and effective strategy for tailor-made polysaccharide production.
8. Kanehisa M., Goto S., Hattori M., Aoki-Kinoshita K.F., Itoh M., Kawashima S., Katayama T., Araki M., and Hirakawa M. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34 (2006) D354-357
9. Kawano T., Koyama S., Hiromu T., Kozutsumi Y., Kawasaki H., Kawashima S., Kawasaki T., and Suzuki A. Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N-glycolylneuraminic acid. J Biol Chem 270 (1995) 16458-16463
10. Collins B.E., Fralich T.J., Itonori S., Ichikawa Y., and Schnaar R.L. Conversion of cellular sialic acid expression from N-acetyl- to N-glycolylneuraminic acid using a synthetic precursor, N-glycolylmannosamine pentaacetate: inhibition of myelin-associated glycoprotein binding to neural cells. Glycobiology 10 (2000) 11-20
11. Irie A., Koyama S., Kozutsumi Y., Kawasaki T., and Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 273 (1998) 15866-15871
12. Chou H.H., Hayakawa T., Diaz S., Krings M., Indriati E., Leakey M., Paabo S.Y.S., Takahata N., and Varki A. Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc Natl Acad Sci U S A 99 (2002) 11736-11741
13. Crocker P.R., and Varki A. Siglecs in the immune system. Immunology 103 (2001) 137-145
14. Keppler O.T., Horstkorte R., Pawlita M., Schmidt C., and Reutter W. Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology 11 (2001) 11R-18R
15. Villavicencio-Lorini P., Laabs S., Danker K., Reutter W., and Horstkorte R. Biochemical engineering of the acyl side chain of sialic acids stimulates integrin-dependent adhesion of HL60 cells to fibronectin. J Mol Med 80 (2002) 671-677
16. Kontou M., Bauer C., Reutter W., and Horstkorte R. Sialic acid metabolism is involved in the regulation of gene expression during neuronal differentiation of PC12 cells. Glycoconjug J 25 (2008) 237-244
17. Schmidt C., Stehling P., Schnitzer J., Reutter W., and Horstkorte R. Biochemical engineering of neural cell surfaces by the synthetic N-propanoyl-substituted neuraminic acid precursor. J Biol Chem 273 (1998) 19146-19152
18. Liu T., Guo Z., Yang Q., Sad S., and Jennings H.J. Biochemical engineering of surface a 2,8 polysialic acid for immunotargeting tumor cells. J Biol Chem 275 (2000) 32832-32836
19. Aich U., and Yarema K.J. Metabolic oligosaccharide engineering: perspectives, applications, and future directions. In: Fraser-Reid B., Tatsuta K., and Thiem J. (Eds). Glycosciences. 2nd ed. (2008), Springer-Verlag 2136-2190. This review of metabolic glycoengineering is intended for the specialist seeking detailed information on this topic.
20. Gabius H.-J., Siebert H.-C., André S., Jiménez-Barbero J., and Rüdiger H. Chemical biology of the sugar code. ChemBioChem 5 (2004) 740-764
21. Gross H.J., and Brossmer R. Enzymatic introduction of a fluorescent sialic acid into oligosaccharide chains of glycoproteins. Eur J Biochem 177 (1988) 583-589
22. Lemieux G.A., and Bertozzi C.R. Chemoselective ligation reactions with proteins, oligosaccharides and cells. Trends Biotechnol 16 (1998) 506-513
23. Mahal L.K., Yarema K.J., and Bertozzi C.R. Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis. Science 276 (1997) 1125-1128
24. Yarema K.J., Mahal L.K., Bruehl R.E., Rodriguez E.C., and Bertozzi C.R. Metabolic delivery of ketone groups to sialic acid residues. Application to cell surface glycoform engineering. J Biol Chem 273 (1998) 31168-31179
25. Sampathkumar S.-G., Li A.V., Jones M.B., Sun Z., and Yarema K.J. Metabolic installation of thiols into sialic acid modulates adhesion and stem cell biology. Nat Chem Biol 2 (2006) 149-152
26. Tanaka Y., and Kohler J.J. Photoactivatable crosslinking sugars for capturing glycoprotein interactions. J Am Chem Soc 130 (2008) 3278-3279
27. Hsu T.-L., Hanson S.R., Kishikawa K., Wang S.-K., Sawa M., and Wong C.-H. Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells. Proc Natl Acad Sci U S A 104 (2007) 2614-2619
28. Saxon E., and Bertozzi C.R. Cell surface engineering by a modified Staudinger reaction. Science 287 (2000) 2007-2010
29. Baskin J.M., Prescher J.A., Laughlin S.T., Agard N.J., Chang P.V., Miller I.A., Lo A., Codelli J.A., and Bertozzi C.R. Copper-free click chemistry for dynamic in vivo imaging. Proc Natl Acad Sci U S A 104 (2007) 16793-16797
30. Laughlin S.T., and Bertozzi C.R. Imaging the glycome. Proc Natl Acad Sci U S A 106 (2009) 12-17. This paper summarizes recent developments in chemistry and biology that are enabling in vivo glycomic imaging.
31. Laughlin S.T., Baskin J.M., Amacher S.L., and Bertozzi C.R. In vivo imaging of membrane-associated glycans in developing zebrafish. Science 320 (2008) 664-667
32. Khidekel N., Ficarro S.B., Peters E.C., and Hsieh-Wilson L.C. Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain. Proc Natl Acad Sci U S A 101 (2004) 13132-13137
33. Han S., Collins B.E., Bengtson P., and Paulson J.C. Homo-multimeric complexes of CD22 revealed by in situ photoaffinity protein-glycan crosslinking. Nat Chem Biol 1 (2005) 93-97
34. Lee J.H., Baker T.J., Mahal L.K., Zabner J., Bertozzi C.R., Wiemar D.F., and Welsh M.J. Engineering novel cell surface receptors for virus-mediated gene transfer. J Biol Chem 274 (1999) 21878-21884
35. Nauman D.A., and Bertozzi C.R. Kinetic parameters for small-molecule drug delivery by covalent cell surface targeting. Biochim Biophys Acta 1568 (2001) 147-154
36. Lemieux G.A., Yarema K.J., Jacobs C.L., and Bertozzi C.R. Exploiting differences in sialoside expression for selective targeting of MRI contrast reagents. J Am Chem Soc 121 (1999) 4278-4279
37. Wang Q., Ekanayaka S.A., Wu J., Zhang J., and Guo Z. Synthetic and immunological studies of 5′-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins. Bioconjug Chem 19 (2008) 2060-2067. This article describes ongoing efforts to exploit monosaccharide analogs to increase the immunogenicity of tumor-associated carbohydrate antigens; this strategy currently represents one of the most advanced efforts to translate metabolic glycoengineering from the laboratory to the clinic.
38. Wang Q., Zhang J., and Guo Z. Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg Med Chem 15 (2007) 7561-7567
39. Dove A. The bittersweet promise of glycobiology. Nat Biotechnol 19 (2001) 913-917
40. Fuster M.M., and Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5 (2005) 526-542
41. Lundquist J.J., and Toone E.J. The cluster glycoside effect. Chem Rev 102 (2002) 555-578
42. Kiessling L.L., and Pohl S. Strength in numbers: non-natural polyvalent carbohydrate derivatives. Chem Biol 3 (1996) 71-77
43. Gabius H.J. Glycans: bioactive signals decoded by lectins. Biochem Soc Trans 36 (2008) 1491-1496. This review summarizes biological recognition events determined by the 'sugar code' (and thereby indirectly provides a perspective on the breadth and mechanisms of cellular processes that can potentially be manipulated by the ability of metabolic glycoengineering to alter lectin function).
44. Liu H., Zhang Z., and Linhardt R.J. Lessons learned from the contamination of heparin. Nat Prod Rep 26 (2009) 313-321
45. Meutermans W., Le G.T., and Becker B. Carbohydrates as scaffolds in drug discovery. ChemMedChem 1 (2006) 1164-1194
46. Lavis L.D. Ester bonds in prodrugs. ACS Chem Biol 3 (2008) 203-206
47. Kim E.J., Sampathkumar S.-G., Jones M.B., Rhee J.K., Baskaran G., and Yarema K.J. Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acetylmannosamine (ManNAc) analogs in Jurkat (human T-lymphoma-derived) cells. J Biol Chem 279 (2004) 18342-18352
48. Aich U., Campbell C.T., Elmouelhi N., Weier C.A., Sampathkumar S.-G., Choi S.S., and Yarema K.J. Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxcity and MUC1 suppression. ACS Chem Biol 3 (2008) 230-240. This paper describes evidence that SCFA-hexosamine analogs used in metabolic glycoengineering have a third (beyond SCFA- and sugar-mediated) mode of action that depends on molecular species consisting of a core sugar with intact ester-linked groups.
49. Sampathkumar S.-G., Campbell C.T., Weier C., and Yarema K.J. Short-chain fatty acid-hexosamine cancer prodrugs: the sugar matters!. Drug Future 31 (2006) 1099-1116
50. Campbell C.T., Aich U., Weier C.A., Wang J.J., Choi S.S., Wen M.M., Maisel K., Sampathkumar S.-G., and Yarema K.J. Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogs inhibits the mobility of metastatic MDA-MB-231 breast cancer cell. J Med Chem 51 (2008) 8135-8147
51. Elmouelhi N., Aich U., Paruchuri V.D.P., Meledeo M.A., Campbell C.T., Wang J.J., Srinivas R., Khanna H.S., and Yarema K.J. Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. J Med Chem 52 (2009) 2515-2530. This paper proposes and provides experimental evidence, that SCFA-hexosamines comprise a versatile platform for drug discovery.
52. Lipinski C.A. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1 (2004) 337-341
53. Laederach A., and Reilly P.J. Specific empirical free energy function for automated docking of carbohydrates to proteins. J Comput Chem 24 (2003) 1748-1757